With flu season on doorstep, what good is oseltamivir anyways?
If you've been paying attention to the literature over the last 6 months, you might feel completely befuddled by all of the conflicting information on osetltamivir (Tamiflu). I know I am!
In the spring of 2014, the Cochrane group published an updated review of data on oseltamivir's effectiveness. This review incorporated previously unpublished and withheld data sets. In short, the Cochrane group found that oseltamivir had no effect on hospitalization rates for influenza. The Cochrane authors argued that the decision to stockpile neuraminidase inhibitors like oseltamivir might be misguided. (For those interested in the full story of the withheld data, I would direct you to this masterful piece.) Additionally, a review in Annals of Internal Medicine found that industry-supported reviews of the drug had more favorable findings and conclusions than studies completed by researchers without a financial conflict of interest.
On the other hand, at least one major review in 2014 found that hospitalized patients treated with oseltamivir derive real benefits including reduced mortality. The CDC's guidelines for this flu season recommend prompt therapy with a neuraminidase inhibitors for high-risk outpatients and for all hospitalized patients with suspected or confirmed influenza. An editorial in this week's NEJM also argues for prompt treatment of pregnant patients.
So what's the deal with oseltamivir anyways? Is every prescription for it just helping to fill Roche's corporate coffers? Or is oseltamivir's routine use justified?
Here's my take. In otherwise healthy adults, there is probably not a role of treating influenza. The relative shortening of a flu-like illness by about one half-day may be of some value to patients, but there is real risk of adverse effects and resistance. I myself probably wouldn't take an oseltamivir script this year -- even though I admit to having placed myself on two separate courses of it over the last several years.
However, I will still feel compelled to treat acutely ill, hospitalized patients or high-risk ambulatory patients with oseltamivir until someone can give me a pretty good reason not to.












